Melanotan II
Neutral, BioHarmony verdict
BioHarmony score 4.5 out of 10
Melanotan II is a fast tanning and sexual-response peptide with a harsher safety tradeoff; Nelson 2012 reported rhabdomyolysis after a 6 mg injection. Its appetite and libido effects may be noticeable, but this report treats unregulated use as high risk.
Read full reportWhat is Melanotan II?
Melanotan II is an unapproved non-selective melanocortin peptide that can darken skin, suppress appetite, and produce sexual-response effects, but the same receptor breadth creates a serious safety problem. Melanotan II activates several melanocortin receptors, including MC1R for pigmentation and central pathways tied to appetite and libido. Melanotan II earns a low score because early human efficacy signals are small and verified case reports include PRES, rhabdomyolysis, renal infarction, melanoma, and dysplastic-nevus proliferation.
From the BioHarmony report, reviewed Sep 20, 2026.
Saved on this device only.
How it is thought to work
Non-selective melanocortin receptor activation
Safety watch-outs
- New or rapidly changing mole, oral pigmentation, or bleeding lesion
- Severe headache, confusion, vision change, chest pain, or neurologic symptoms
- Priapism, severe abdominal pain, dark urine, or muscle pain after dosing
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Melanotan II yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (3)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound Curriculum Dr. William Seeds,
- Muscle Building in Midlife, Joint Regeneration, Peptide Protocols, and Why Osteoarthritis Is Not Wear and Tear Dr. Elizabeth Yurth,
- Melanotan 1 vs Melanotan 2: Which Peptide Is Right for You? Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA identifies immunogenicity and peptide-impurity concerns for compounded melanotan II and cites published reports of serious adverse events.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risks U.S. Food and Drug Administration,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.